RADIUS® | IMPROVING LIFE FROM THE INSIDE OUT

Please click on program name to learn more ▼

BA058 Injection
Bone anabolic candidate for osteoporosis

Daily subcutaneous injection of hPTHrP analog, BA058

Phase III clinical trial ongoing

BA058 Injection is Radius' novel, proprietary peptide analog of hPTHrP (human parathyroid hormone-related protein) in a Phase III clinical trial for the treatment of postmenopausal osteoporosis. There is increasing evidence that hPTHrP is a critical cytokine for promoting new bone formation, with a distinct role from PTH (which primarily regulates calcium homeostasis and bone resorption) and the ability to rebuild bone with low associated risk of inducing hypercalcemia as a side effect.
In Phase 2 clinical trials, BA058 Injection produced faster and greater bone mineral density (BMD) at the spine and hip after six months and 12 months of therapy, with greater BMD gains relative to Forteo®, the reference drug used in the study.
BA058 potentially offers a number of important advantages as a new treatment for osteoporosis, including superior efficacy in building new bone rapidly, and a desirable safety profile due to minimized risk of hypercalcemia and no significant bone resorption.

BA058 Microneedle Patch
Bone anabolic candidate for osteoporosis

Transdermal delivery of hPTHrP analog, BA058

Phase I clinical trials completed

The BA058 Microneedle Patch is a short wear-time transdermal patch based on 3M's patented Microstructured Transdermal System technology to administer BA058 through the skin as an alternative to subcutaneous injection. The once-daily BA058 Microneedle Patch is expected to offer superior efficacy in building new bone rapidly and a desirable safety profile due to minimized risk of hypercalcemia and no significant bone resorption. The BA058 Microneedle Patch is intended to provide a more convenient treatment alternative to injection that may also promote treatment compliance among osteoporosis patients.

RAD1901
Novel tissue-selective estrogen receptor modulator for menopausal hot flashes

RAD1901 is potentially the first of a new class of selective estrogen receptor modulators (SERMs) that could relieve vasomotor symptoms (hot flashes) without the side effects associated with hormone therapy. In preclinical studies, RAD1901 demonstrated the potential to reduce or prevent the hot flashes associated with menopause with a simultaneous bone-protective effect, without stimulating breast or uterine tissues. In Phase 1 clinical trials, RAD1901 showed a favorable safety profile. In a four-week Phase 2a study, RAD1901 established clinical proof of concept, achieving a statistically significant reduction in frequency of moderate and severe hot flashes.

Development stage: Radius plans to confirm results of the Phase 2a study through a larger Phase 2 clinical trial with a longer duration of treatment.

RAD140
Novel bone & muscle anabolic agent for osteoporosis and aging-associated frailty

RAD140 is a selective androgen receptor modular, or SARM, that is an orally active androgen agonist on muscle and bone and is a potential treatment for age-related muscle loss, frailty, weight loss associated with cancer cachexia, and osteoporosis.

Development stage: Pre-IND.

201 Broadway, 6th Floor, Cambridge, MA 02139
Tel: (617) 551-4700 | Fax: (617) 551-4701